Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin
Open accessThe DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To examine the efficacy and safety of adding the once-daily glucagon-like peptide-1 receptor agonist (GLP-1RA) lixisenatide to established basal insulin therapy alone or together with metformin, in people with type 2 diabetes and elevated glycated hemoglobin (HbA1c). RESEARCH DESIGN AND METHODS: We conducted a double-blind, parallel-group, placebo-controlled trial. Patients (n = 495) with established basal insulin therapy but inadequate glycemic control were randomized to add lixisenatide 20 μg or placebo for 24 weeks. Basal insulin dosage was unchanged except to limit hypoglycemia. HbA1c reduction from baseline was the primary end point. RESULTS: Mean duration of diabetes was 12.5 years, duration of insulin use was 3.1 years, insulin dosage was 55 units/day, and baseline HbA1c was 8.4%. With lixisenatide, the placebo-corrected change of HbA1c from baseline was –0.4% (95% CI –0.6 to –0.2; P = 0.0002), and mean HbA1c at end point was 7.8%. HbA1c <7.0% (53 mmol/mol) was attained by more lixisenatide (28%) than placebo (12%; P < 0.0001) participants. Lixisenatide reduced plasma glucose levels after a standardized breakfast (placebo-corrected reduction, –3.8 mmol/L; P < 0.0001); seven-point glucose profiles showed a reduction persisting through the day. Reductions in body weight (placebo corrected, –1.3 kg; P < 0.0001) and insulin dosage (–3.7 units/day; P = 0.012) were greater with lixisenatide. Main adverse events (AEs) with lixisenatide were gastrointestinal. Symptomatic hypoglycemia was 28% for lixisenatide and 22% for placebo; 4 of 328 subjects (1.2%) had severe hypoglycemia with lixisenatide vs. 0 of 167 with placebo. CONCLUSIONS: By improving HbA1c and postprandial hyperglycemia without weight gain in type 2 diabetes with inadequate glycemic control despite stable basal insulin, lixisenatide may provide an alternative to rapid-acting insulin or other treatment options.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“At the same time, the research of GetGoal-Duo1 and GetGoal-L also found that when the basic insulin treatment was not effective, the combination of LIXI could not only significantly improve fasting blood glucose and glycosylated hemoglobin but also significantly reduce weight, with the weight dropping by 0.9 kg and 1.3 kg respectively (71).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [71]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Self-citationRiddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Global guideline for type 2 diabetes
(2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.10.001 · Cited by 1,064
Rodbard, H. W., Jellinger, P. S., Davidson, J. A., Einhorn, D., Garber, A. J., Grunberger, G., Handelsman, Y., Horton, E. S., Lebovitz, H., Levy, P., et al. (2009) · Endocrine Practice · doi:10.4158/ep.15.6.540 · Cited by 942
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetologia · doi:10.1007/s00125-008-1157-y · Cited by 712
Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes
Holman, R. R., Thorne, K. I., Farmer, A. J., Davies, M. J., Keenan, J. F., Paul, S., & Levy, J. C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa075392 · Cited by 710
Three-year efficacy of complex insulin regimens in type 2 diabetes
Holman, R. R., Farmer, A. J., Davies, M. J., Levy, J. C., Darbyshire, J. L., Keenan, J. F., & Paul, S. K. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905479 · Cited by 667
Buse, J. B., Bergenstal, R. M., Glass, L. C., Heilmann, C. R., Lewis, M. S., Kwan, A. Y. M., Hoogwerf, B. J., & Rosenstock, J. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-2-201101180-00300 · Cited by 506
Self-citationNauck, M. A., Kemmeries, G., Holst, J. J., & Meier, J. J. (2011) · Diabetes · doi:10.2337/db10-0474 · Cited by 392 · cited 1×
“However, slowing of gastric emptying appears to be greater with short-acting than with longacting GLP-1RAs (13), possibly related to the observation that, with time, continuous exposure of GLP-1 leads to a reduction in its effect on gastric emptying (14).”
Research works printed but not linked: 1
- Ratner, 2009, Post-meal pharmacodynamic profile of ACE0010, a once-daily GLP-1 receptor agonst, in patients with type 2 diabetes inadequally controlled on metformin, Diabetologia, 52, S60
Cited by
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409
Self-citationUpdate on the treatment of type 2 diabetes mellitus
Marín-Peñalver, J. J., Martín-Timón, I., Sevillano-Collantes, C., & Cañizo-Gómez, F. J. D. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i17.354 · Cited by 647
Filippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560
Glucagon-like peptide 1 in health and disease
Andersen, A., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0016-2 · Cited by 543
Htike, Z. Z., Zaccardi, F., Papamargaritis, D., Webb, D. R., Khunti, K., & Davies, M. J. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12849 · Cited by 416
Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
Tahrani, A. A., Barnett, A. H., & Bailey, C. J. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.86 · Cited by 398
Eng, C., Kramer, C. K., Zinman, B., & Retnakaran, R. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61335-0 · Cited by 383
Emerging role of GLP-1 agonists in obesity: A comprehensive review of randomised controlled trials
Popoviciu, M.-S., Păduraru, L., Yahya, G., Metwally, K., & Cavalu, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310449 · Cited by 280
Rosenstock, J., Aronson, R., Grunberger, G., Hanefeld, M., Piatti, P., Serusclat, P., Cheng, X., Zhou, T., Niemoeller, E., Souhami, E., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0917 · Cited by 272
“The rate of nausea in the iGlarLixi group was also lower than those observed in previous studies where Lixi was co-administered with basal insulin as separate injections (25–27% and 8– 9%, respectively) (14,21,22).”
Self-citationMechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Liu, Q. K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1431292 · Cited by 265
Meier, J. J., Rosenstock, J., Hincelin-Méry, A., Roy-Duval, C., Delfolie, A., Coester, H.-V., Menge, B. A., Forst, T., & Kapitza, C. (2015) · Diabetes Care · doi:10.2337/dc14-1984 · Cited by 262
Self-citationAroda, V. R., Rosenstock, J., Wysham, C., Unger, J., Bellido, D., González-Gálvez, G., Takami, A., Guo, H., Niemoeller, E., Souhami, E., et al. (2016) · Diabetes Care · doi:10.2337/dc16-1495 · Cited by 260
“treatment, generally in the 25–30% range (7,9,12).”
Self-citationRosenstock, J., Raccah, D., Korányi, L., Maffei, L., Boka, G., Miossec, P., & Gerich, J. E. (2013) · Diabetes Care · doi:10.2337/dc12-2709 · Cited by 253
Self-citationAroda, V. R. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13162 · Cited by 253
“Several RCTs (GetGoal-L, Goal-L-Asia, and GetGoal-Duo-1) demonstrated the complementary effects of lixisenatide with basal insulin, showing that the combination effectively targeted both fasting glucose (through basal insulin) and postprandial glucoses (through lixisenatide's action).(42,43,52) With its primary postpr…”
GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
Wang, J.-Y., Wang, Q.-W., Yang, X.-Y., Yang, W., Li, D.-R., Jin, J.-Y., Zhang, H.-C., & Zhang, X.-F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1085799 · Cited by 248
Cefalu, W. T., Bray, G. A., Home, P. D., Garvey, W. T., Klein, S., Pi-Sunyer, F. X., Hu, F. B., Raz, I., Van Gaal, L., Wolfe, B. M., et al. (2015) · Diabetes Care · doi:10.2337/dc15-1081 · Cited by 243
Self-citationGlucagon‐like peptide‐1 receptor agonists in type 2 diabetes treatment: are they all the same?
Gentilella, R., Pechtner, V., Corcos, A., & Consoli, A. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3070 · Cited by 227
“However, these antibodies did not affect HbA1c reductions with, or the tolerability of, lixisenatide.(19,22,25) Antialbiglutide and antiliraglutide antibodies were observed in 4% and 8.”
BackgroundDiamant, M., Nauck, M. A., Shaginian, R., Malone, J. K., Cleall, S., Reaney, M., de Vries, D., Hoogwerf, B. J., MacConell, L., Wolffenbuttel, B. H. R., et al. (2014) · Diabetes Care · doi:10.2337/dc14-0876 · Cited by 228
“Randomization, mean (SD) 137 (16) 135 (15)”
2021 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
Hur, K. Y., Moon, M. K., Park, J. S., Kim, S.-K., Lee, S.-H., Yun, J.-S., Baek, J. H., Noh, J., Lee, B.-W., Oh, T. J., et al. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0156 · Cited by 226
Lorenz, M., Pfeiffer, C., Steinsträßer, A., Becker, R. H. A., Rütten, H., Ruus, P., & Horowitz, M. (2013) · Regulatory Peptides · doi:10.1016/j.regpep.2013.04.001 · Cited by 149
Pinget, M., Goldenberg, R., Niemoeller, E., Muehlen‐Bartmer, I., Guo, H., & Aronson, R. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12121 · Cited by 139
“The results of this study are consistent with, and extend the results of, previously reported phase III studies of lixisenatide in patients with T2DM, either untreated [14] or inadequately controlled on metformin alone [13,15,21], on sulphonylurea therapy with or without metformin [9], and on basal insulin plus oral a…”
Self-citationPozzilli, P., Norwood, P., Jódar, E., Davies, M. J., Ivanyi, T., Jiang, H., Woodward, D. B., & Milicevic, Z. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12937 · Cited by 137
“Similar results were observed with once daily lixisenatide or once weekly albiglutide [12, 13] and with fixed-combinations of insulin degludec and liraglutide or glargine and lixisenatide [14, 15].”
ResultRosenstock, J., Guerci, B., Hanefeld, M., Gentile, S., Aronson, R., Tinahones, F. J., Roy-Duval, C., Souhami, E., Wardecki, M., Ye, J., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0014 · Cited by 133
Self-citationRosenstock, J., Hanefeld, M., Shamanna, P., Min, K. W., Boka, G., Miossec, P., Zhou, T., Muehlen-Bartmer, I., & Ratner, R. E. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.01.012 · Cited by 130
Self-citation2023 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
Choi, J. H., Lee, K. A., Moon, J. H., Chon, S., Kim, D. J., Kim, H. J., Kim, N. H., Seo, J. A., Kim, M. K., Lim, J. H., et al. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0282 · Cited by 150
Hu, W., Song, R., Cheng, R., Liu, C., Guo, R., Tang, W., Zhang, J., Zhao, Q., Li, X., & Liu, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.927859 · Cited by 127
“, 2013 (50) NCT00715624 125 Lixisenatide Placebo 1/328 0/167 57.”
Maiorino, M. I., Chiodini, P., Bellastella, G., Capuano, A., Esposito, K., & Giugliano, D. (2017) · Diabetes Care · doi:10.2337/dc16-1957 · Cited by 125
“Four trials (12,13,15,20) tested the superiority of the combination (GLP-1RA and in-”
Glucagon-Like Peptide 1 Receptor Agonists and Mental Health: A Systematic Review and Meta-Analysis
Pierret, A. C. S., Mizuno, Y., Saunders, P., Lim, E., De Giorgi, R., Howes, O. D., McCutcheon, R. A., McGowan, B., Sen Gupta, P., Smith, D., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.0679 · Cited by 116
Maloney, A., Rosenstock, J., & Fonseca, V. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1307 · Cited by 115
“This is because it is not uncommon that patients modify their insulin dose dependent on the efficacy of their randomized treatment, with more efficacious treatments resulting is less insulin use.(42,43) Thus, final comparisons between treatments in these studies are confounded with differential insulin usage (a simila…”
BackgroundSelf-citationScott, R. A., Freitag, D. F., Li, L., Chu, A. Y., Surendran, P., Young, R., Grarup, N., Stancáková, A., Chen, Y., Varga, T. V., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad3744 · Cited by 118
New forms of insulin and insulin therapies for the treatment of type 2 diabetes
Cahn, A., Miccoli, R., Dardano, A., & Prato, S. D. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00097-2 · Cited by 114
Ahmann, A., Rodbard, H. W., Rosenstock, J., Lahtela, J. T., de Loredo, L., Tornøe, K., Boopalan, A., Nauck, M. A., & on behalf of the NN2211‐3917 Study Group (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12539 · Cited by 104
Self-citationTran, K., Park, Y. I., Pandya, S., Muliyil, N. J., Jensen, B. D., Huynh, K., & Nguyen, Q. P. H. (2017) · PubMed · Cited by 124
Cao, C., Yang, S., & Zhou, Z. (2019) · Endocrine · doi:10.1007/s12020-019-02055-z · Cited by 99
Miyagawa, J., Odawara, M., Takamura, T., Iwamoto, N., Takita, Y., & Imaoka, T. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12534 · Cited by 96
“The incidence of antibodies in the present study was lower than in other GLP-1 compounds with an exendin-4 backbone (exenatide twice daily, 44–60% [32]; exenatide once weekly, 61–68% [33,34]; and lixisenatide, approximately 70% [35]); the lower incidence in the present study is probably attributable to the design of t…”
The application of sulfur-containing peptides in drug discovery
Zhao, J., & Jiang, X. (2018) · Chinese Chemical Letters · doi:10.1016/j.cclet.2018.05.026 · Cited by 102
GLP‐1 Receptor Agonists for Type 2 Diabetes Mellitus: Recent Developments and Emerging Agents
Trujillo, J. M., & Nuffer, W. (2014) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1507 · Cited by 95
“A study evaluated the addition of lixisenatide 20 lg once/day in patients with T2D inadequately controlled with basal insulin with or without metformin in the GetGoal-L study.(9) After 24 weeks of treatment, the change in A1c from baseline was greater in the lixisenatide group than in the placebo group ( 0.”
Bentley-Lewis, R., Aguilar, D., Riddle, M. C., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Johnston, P., Køber, L. V., Lawson, F., et al. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.02.002 · Cited by 98
Self-citationHuthmacher, J. A., Meier, J. J., & Nauck, M. A. (2020) · Diabetes Care · doi:10.2337/dc20-0498 · Cited by 91
Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer? A Systematic Review and Meta-analysis
Piccoli, G. F., Mesquita, L. A., Stein, C., Aziz, M., Zoldan, M., Degobi, N. A. H., Spiazzi, B. F., Lopes Junior, G. L., Colpani, V., & Gerchman, F. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa891 · Cited by 81
Rosenstock, J., Diamant, M., Aroda, V. R., Silvestre, L., Souhami, E., Zhou, T., Perfetti, R., Fonseca, V., & for the LixiLan PoC Study Group (2016) · Diabetes Care · doi:10.2337/dc16-0046 · Cited by 86
Self-citationGiorda, C. B., Nada, E., & Tartaglino, B. (2014) · Endocrine · doi:10.1007/s12020-014-0179-0 · Cited by 89
Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies
Gerich, J. (2013) · International Journal of General Medicine · doi:10.2147/ijgm.s51665 · Cited by 77
“0857]).(80,85) Similarly, in the GetGoalDuo 1 study (898 patients, 466 male/432 female; mean age 56±10 years), once-daily lixisenatide added to consistently titrated insulin glargine plus metformin with or without a thiazolidinedione significantly improved HbA 1c and 2-hour PPG compared with placebo, with signif icant…”
Novel agents for the treatment of type 2 diabetes
DeFronzo, R. A., Triplitt, C. L., Abdul-Ghani, M., & Cersosimo, E. (2014) · Diabetes Spectrum · doi:10.2337/diaspect.27.2.100 · Cited by 83
Lind, M., Hirsch, I. B., Tuomilehto, J., Dahlqvist, S., Ahrén, B., Torffvit, O., Attvall, S., Ekelund, M., Filipsson, K., Tengmark, B.-O., et al. (2015) · BMJ · doi:10.1136/bmj.h5364 · Cited by 82
Guja, C., Frías, J. P., Somogyi, A., Jabbour, S., Wang, H., Hardy, E., & Rosenstock, J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13266 · Cited by 78
Self-citationMoon, J. S., Kang, S., Choi, J. H., Lee, K. A., Moon, J. H., Chon, S., Kim, D. J., Kim, H. J., Seo, J. A., Kim, M. K., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0249 · Cited by 90
Owens, D., Monnier, L., & Bolli, G. (2013) · Diabetes & Metabolism · doi:10.1016/j.diabet.2013.09.004 · Cited by 82
Rosenstock, J., Nino, A., Soffer, J., Erskine, L., Acusta, A., Dole, J., Carr, M. C., Mallory, J., & Home, P. (2020) · Diabetes Care · doi:10.2337/dc19-2316 · Cited by 73
Self-citationAdetunji, O., Kalra, S., Baruah, M., Sahay, R., Unnikrishnan, A., & Uppal, S. (2016) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.176351 · Cited by 71
Yu Pan, C., Han, P., Liu, X., Yan, S., Feng, P., Zhou, Z., Lv, X., Tian, H., Jin Kui, Y., Su, B., et al. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2541 · Cited by 71
“Lixisenatide has also previously been reported to have a beneficial effect on body weight [24,25,27,39].”
Self-citationPrice, H. C., Blüher, M., Prager, R., Phan, T., Thorsted, B. L., Schultes, B., & for the EXTRA study group (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13182 · Cited by 71
Monnier, L., & Colette, C. (2015) · Diabetes & Metabolism · doi:10.1016/s1262-3636(16)30003-9 · Cited by 78
de Wit, H. M., Vervoort, G., Jansen, H. J., de Grauw, W. J. C., de Galan, B. E., & Tack, C. J. (2014) · Diabetologia · doi:10.1007/s00125-014-3302-0 · Cited by 75
“This could also have prevented a higher rate of hypoglycaemia in the liraglutide-treated group, the absence of which has been described previously [17, 19, 22, 23, 25].”
A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications
Haddad, F., Dokmak, G., Bader, M., & Karaman, R. (2023) · Life · doi:10.3390/life13041012 · Cited by 79
“In GetGoal-L, a global, double-blinded, randomized, phase 3-trial, 495 T2DM patients on basal insulin therapy were randomly assigned to receive either placebo or 20 μg of lixisenatide once day (following the 2-step titration approach) [168].”
BackgroundMethodBajaj, H. S., Venn, K., Ye, C., Patrick, A., Kalra, S., Khandwala, H., Aslam, N., Twum-Barima, D., & Aronson, R. (2017) · Diabetes Care · doi:10.2337/dc16-1582 · Cited by 65
Self-citationGlucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes
Lovshin, J. A. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.08.242 · Cited by 74
Potential side effects to GLP-1 agonists: understanding their safety and tolerability
Consoli, A., & Formoso, G. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.987122 · Cited by 63
“1 [36,42,49,100-104] Liraglutide 20 8 11 -- 14 5 -- 9 [68] 10.”
Can medical therapy mimic the clinical efficacy or physiological effects of bariatric surgery?
Miras, A. D., & le Roux, C. W. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.205 · Cited by 64
Gluud, L. L., Knop, F. K., & Vilsbøll, T. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-005325 · Cited by 59
Importance of Postprandial Glucose in Relation to A1C and Cardiovascular Disease
Hershon, K. S., Hirsch, B. R., & Odugbesan, O. (2019) · Clinical Diabetes · doi:10.2337/cd18-0040 · Cited by 67
Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes
Ahrén, B. (2014) · World J Diabetes · doi:10.4239/wjd.v5.i1.40 · Cited by 51
Owens, D. R., Monnier, L., & Barnett, A. H. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12977 · Cited by 57
Basal Insulin Intensification in Patients with Type 2 Diabetes: A Review
Meece, J. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0395-3 · Cited by 51
Raccah, D., Miossec, P., Esposito, V., Niemoeller, E., Cho, M., & Gerich, J. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2588 · Cited by 50
“24-week randomized, controlled trial NCT00715624 GetGoal-L [32] Lixisenatide versus placebo added to existing basal insulin±MET.”
Self-citationLixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects
Becker, R. H. A., Stechl, J., Steinstraesser, A., Golor, G., & Pellissier, F. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2647 · Cited by 49
van Baar, A. C. G., Meiring, S., Smeele, P., Vriend, T., Holleman, F., Barlag, M., Mostafavi, N. S., Tijssen, J. G. P., Soeters, M. R., Nieuwdorp, M., et al. (2020) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2020.12.021 · Cited by 51
Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance
Tella, S. H., & Rendell, M. S. (2015) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018815580257 · Cited by 46
Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis
Charbonnel, B., Bertolini, M., Tinahones, F. J., Domingo, M. P., & Davies, M. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.07.007 · Cited by 48
Werner, U. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.06.003 · Cited by 47
“…al., 2012), as add-on to oral antidiabetic drugs (Ahrén, Dimas, Miossec, Saubadu, & Aronson, 2013; Bolli et al., 2011; Pinget et al., 2013; Ratner et al., 2011) and in combination with basal insulin (Riddle et al., 2013a; Riddle et al., 2013b; Seino, Min, Niemoeller, Takami, & Investigators, 2012).”
BackgroundZhang, Z., Zhang, Q., Tan, Y., Chen, Y., Zhou, X., Liu, S., & Yu, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1149328 · Cited by 46
“09) (56) T2DM 24week Lixisenatide 20ug qd Placebo 495 57±10 12.”
How much is too much? Outcomes in patients using high‐dose insulin glargine
Reid, T., Gao, L., Gill, J., Stuhr, A., Traylor, L. B., Vlajnic, A., & Rhinehart, A. S. (2015) · International Journal of Clinical Practice · doi:10.1111/ijcp.12747 · Cited by 48
GLP-1 as a target for therapeutic intervention
Rajeev, S. P., & Wilding, J. P. H. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.08.005 · Cited by 45
Hinnen, D. (2015) · Clinical Diabetes · doi:10.2337/diaclin.33.4.175 · Cited by 42
“4% reduction in A1C from baseline versus placebo on a background of basal insulin with or without metformin (9).”
Xia, L., Shen, T., Dong, W., Su, F., Wang, J., Wang, Q., Niu, S., & Fang, Y. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108904 · Cited by 40
Chubb, B., Gupta, P., Gupta, J., Nuhoho, S., Kallenbach, K., & Orme, M. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01034-w · Cited by 39
Is there a justification for classifying GLP-1 receptor agonists as basal and prandial?
Miñambres, I., & Pérez, A. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0204-6 · Cited by 39
Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review
Østergaard, L., Frandsen, C. S., & Madsbad, S. (2016) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1121808 · Cited by 38
“HbA1c and body weight data are presented in Table 2.[45] Taken together, the results from the current trials investigating lixisenatide versus placebo have shown better glycemic control in T2DM patients on OAD and insulin therapy via the lowering of HbA1c and FPG.”
The FLAT-SUGAR Trial Investigators (2015) · Diabetes Care · doi:10.2337/dc14-2689 · Cited by 39
Meneilly, G. S., Roy-Duval, C., Alawi, H., Dailey, G., Bellido, D., Trescoli, C., Manrique Hurtado, H., Guo, H., Pilorget, V., Perfetti, R., et al. (2017) · Diabetes Care · doi:10.2337/dc16-2143 · Cited by 38
Bolli, G. B., & Owens, D. R. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12253 · Cited by 36
“Lixisenatide is a once-daily prandial GLP-1 RA for the treatment of adults with T2DM [40].”
InfluentialInsulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes
Gough, S. C. L., Jain, R., & Woo, V. C. (2015) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2016.1113129 · Cited by 40
Palanisamy, S., Yien, E. L. H., Shi, L., Yi, L., Qi, S. H., Soon, L., Lun, T. W., & Chen, Y. N. (2018) · Pharmacy · doi:10.3390/pharmacy6030057 · Cited by 48
“[79] 24-week, randomized, double-blind, placebo-controlled T2DM with established basal insulin therapy but inadequate glycemic control.”
BackgroundLixisenatide in type 2 diabetes: latest evidence and clinical usefulness
Anderson, S. L., & Trujillo, J. M. (2016) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622315609312 · Cited by 36
Busch, C. B. E., Meiring, S., van Baar, A. C. G., Holleman, F., Nieuwdorp, M., & Bergman, J. J. G. H. M. (2024) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2024.04.2904 · Cited by 39
Li, W., Chen, X., Xie, X., Xu, M., Xu, L., Liu, P., & Luo, B. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001197 · Cited by 35
“Rosenstock et al,2015 NCT01011868 Empagliflozin (10/25 mg) matching placebo Matching placebo 78 324 (138/186) 170 (80/90) 494 (44) C”
The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus
Christensen, M., Miossec, P., Larsen, B. D., Werner, U., & Knop, F. K. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.942638 · Cited by 34
“Results of clinical trials where lixisenatide was combined with basal insulin showed that HbA1c reductions were significantly greater than with basal insulin alone, mainly due to significant PPG reductions, whereas rates of symptomatic hypoglycemia did not increase appreciably [63,64,66].”
Self-citationMaiorino, M. I., Chiodini, P., Bellastella, G., Scappaticcio, L., Longo, M., Giugliano, D., & Esposito, K. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.06.009 · Cited by 36
Yang, W., Min, K. W., Zhou, Z., Li, L., Xu, X., Zhu, D., Rao, A. V., Murthy, L. S., Zhang, N., Li, I., et al. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13072 · Cited by 37
“GetGoal-L, which enrolled a global population with T2D, and GetGoal-L-Asia, were double-blind, parallel-group, placebo-controlled trials investigating the effects of lixisenatide added to BI.(18,22) The present trial, GetGoal-L-C, follows a similar design but investigates a more targeted population with the objective…”
InfluentialSelf-citationIncretin-based therapies for obesity treatment
de Mello, A. H., Prá, M. D., Cardoso, L. C., Schraiber, R. D. B., & Rezin, G. T. (2015) · Metabolism · doi:10.1016/j.metabol.2015.05.012 · Cited by 36
Cimmaruta, D., Maiorino, M., Scavone, C., Sportiello, L., Rossi, F., Giugliano, D., Esposito, K., & Capuano, A. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1221402 · Cited by 33
“GetGoal-Duo L study [28] was a 24-week RCT in which 495 patients with established basal insulin therapy were randomized to lixisenatide 20 μg or placebo.”
Li, Z., Zhang, Y., Quan, X., Yang, Z., Zeng, X., Ji, L., Sun, F., & Zhan, S. (2016) · PLOS ONE · doi:10.1371/journal.pone.0154206 · Cited by 33
“60 Riddle MC, 2013 [90] Placebo,Lixisenatide 1, 2, 3, 4 495 Met+/-SU+/-TZD 24 57 12.”
Raccah, D., Lin, J., Wang, E., Germé, M., Perfetti, R., Bonadonna, R. C., de Pablos-Velasco, P. L., Roussel, R., & Rosenstock, J. (2013) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.10.003 · Cited by 33
Self-citationNew Developments in Insulin Therapy for Type 2 Diabetes
SORLI, C. H. (2014) · The American Journal of Medicine · doi:10.1016/j.amjmed.2014.07.006 · Cited by 34
Schmidt, L. J., Habacher, W., Augustin, T., Krahulec, E., & Semlitsch, T. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12269 · Cited by 31
“Results of the Get-Goal-L study suggest this effect is less pronounced after other meals of the day, according to the 7-point self-measurement of plasmareferenced glucose (SMPG) [57].”
BackgroundÅhrén, B., Gautier, J., Berria, R., Stager, W., Aronson, R., & Bailey, C. J. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12290 · Cited by 33
“2 mmol/l, respectively [22,23]; whereas the mean treatment difference versus placebo for PPG reduction in GetGoal-L-Asia was more pronounced at −7.”
Self-citationWang, T., Wang, F., Zhou, J., Tang, H., & Giovenale, S. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2804 · Cited by 34
Lin, J., Lingohr-Smith, M., & Fan, T. (2016) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s117200 · Cited by 31
Setty, S. G., Crasto, W., Jarvis, J., Khunti, K., & Davies, M. J. (2016) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2015-133716 · Cited by 37
Impact of Current and Emerging Glucose-Lowering Drugs on Body Weight in Type 2 Diabetes
Lau, D. C. W., & Teoh, H. (2015) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2015.09.090 · Cited by 34
Metadata
- Authors
- Riddle, M. C., Aronson, R., Home, P., Marre, M., Niemoeller, E., Miossec, P., Ping, L., Ye, J., & Rosenstock, J.
- Affiliations
- Oregon Health & Science University (US)
- LMC Diabetes & Endocrinology (Canada) (CA)
- Newcastle University (GB)
- Inserm (FR)
- Sanofi (Germany) (DE)
- Sanofi (France) (FR)
- Sanofi (United States) (US)
- Medical City Dallas Hospital (US)
- Corresponding author
- Riddle, Matthew C.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-08-13
- Volume
- 36
- Issue
- 9
- Pages
- 2489-2496
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3747925
- OpenAlex
- W2106709036
- Cited by
- 288
- References
- 29
- Citations by year
- 2026: 6 · 2025: 11 · 2024: 9 · 2023: 8 · 2022: 7 · 2021: 11 · 2020: 11 · 2019: 12 · 2018: 32 · 2017: 41 · 2016: 36 · 2015: 44 · 2014: 39 · 2013: 20
- FWCI
- 36.44
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- lixisenatide, type 2 diabetes, basal insulin, GLP-1 receptor agonists, glycemic control, HbA1c, postprandial hyperglycemia, hypoglycemia, weight loss, insulin dose reduction, metformin, gastrointestinal adverse effects, adjunctive therapy, glycemic variability, glycemic variability index
- MeSH terms
- Glucagon-Like Peptide-2 Receptor, Aged, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Administration Schedule, Female, Humans, Hypoglycemic Agents, Insulin, Male, Middle Aged, Peptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.